Albertsons beats fourth quarter profit expectations, revenue falls short

Albertsons beat Q4 adjusted EPS at $0.48 versus $0.43 consensus, but revenue came in slightly light at $20.3 billion versus $20.49 billion expected. Fiscal 2026 guidance was mixed: adjusted EPS midpoint of $2.27 is slightly below the $2.29 consensus, while sales growth is forecast at 0.0% to 1.0% and adjusted EBITDA at $3.850 billion to $3.925 billion. The company also raised its quarterly dividend 13% to $0.17 and expanded buybacks to $2.0 billion, while shares rose 0.5% premarket.

Analysis

ACI is showing the classic “good enough to de-risk, not good enough to rerate” setup: the quarter validates margin resilience and capital return capacity, but the forward guide still embeds a regulatory drag that likely caps multiple expansion until investors see evidence the pharmacy headwind is manageable. In other words, this is less a clean fundamental inflection than a valuation support story — the market can justify a higher floor on buybacks/dividend growth, but probably won’t pay up aggressively for low-single-digit comp growth with a 150 bps policy overhang.

The second-order winner is the grocery basket’s private-label and digital mix peers. If ACI can still post online growth and loyalty expansion while pharmacy is under pressure, it suggests the battleground is shifting toward retention economics rather than pure price, which is favorable for operators with scale, data, and higher margin own-label penetration. The pressure point is regional operators with weaker pharmacy economics or less balance-sheet flexibility; they are more exposed to the same reimbursement regime without ACI’s capital return cushion.

The key risk is timing: the earnings quality support from capital returns is immediate, while the regulatory headwind is a multi-quarter to multi-year drag. That asymmetry means the stock can grind higher on buyback/dividend support in the near term, but any guide-down on next quarter comps or evidence that pharmacy weakness is spreading into front-end traffic would quickly unwind the thesis. The contrarian angle is that consensus may be underestimating how much free cash flow can be reaccelerated by the extra week, digital mix, and operating discipline, making the current valuation too anchored to depressed near-term comp expectations rather than normalized cash yield.

From a trading perspective, this favors a cash-yield / capital-return long rather than a momentum chase. The setup is more attractive on pullbacks after the open than on a gap-up, because the upside depends on incremental estimate revisions and continued buyback execution rather than a one-time headline beat. If the market overreacts to the slightly soft guide, that should create a favorable entry for a multi-week mean-reversion trade.

Key Decisions for Investors

• Buy ACI on 1-2% post-earnings pullbacks over the next 3-5 trading days; target a 6-10% move as capital-return support and estimate revisions reprice the stock, with downside limited if EBITDA guidance holds.
• Pair trade: long ACI / short a weaker regional grocer or pharmacy-exposed retailer basket for 1-3 months, betting that scale plus buybacks insulate ACI better from reimbursement pressure and comp volatility.
• Use a covered-call overlay on ACI for the next 30-60 days if already long; the stock likely has more upside floor than ceiling until investors see proof that comps can reaccelerate.
• If ACI breaks down on volume after the guide, reduce exposure quickly — the thesis is sensitive to any evidence that pharmacy headwinds are spreading into front-end traffic, which would compress the multiple back toward low-growth food retail.
• Look for confirmation from next two monthly retail checks and peer pharmacy commentary; if reimbursement pressure proves less severe than feared, ACI has room for another 5-8% rerating on forward FCF yield.